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Objectives
The number of elderly patients with breast cancer is
increasing. The purpose of this study was to evaluate the
outcome of treatment of elderly women with breast can-
cer. We have explored the clinical and biologic character-
istics of a group of patients aged 65 years and over affected
with breast cancer. We have also identified specific subsets
of elderly patients with breast cancer who have survival
similar to that expected in the general population irre-
spective of disease status.
Materials and methods
We considered 155 patients aged 65 year and over, with
an average of 74.1 year (range 65–87), treated at the
Department of Surgical Sciences, Organ Transplantation
and Advanced Technologies, Oncology Surgery Unit, Uni-
versity of Catania, Italy. The therapeutic outcome was
established after the evaluation of the breast cancer's
stage, according to the TNM classification. Thirty patients
of the 155 belonged to the I stage, 40 to the II, 67 to the
III and 18 to the IV stage. For T1 or T2 tumors we per-
formed a quadrantectomy, followed by radiotherapy
treatment on the residual breast tissue. For T3 tumors it
has been performed a modified radical mastectomy, while
in T4 we opted for a primary chemotherapy followed by a
modified radical mastectomy for patients M0, or simple
mastectomy for those M1.
Results
The most frequent histological aspect of breast cancer was
lobular, tubular and mucinous cancer, as well as mixed
ductal-lobular. The positivity for hormone receptors (ER)
was 74% (111 patients). According to the pathological
and biological features, and after oncological evaluation,
patients underwent adjuvant chemotherapy (CMF, FEC)
and/or hormonal therapy (tamoxifen). The average fol-
low-up has been 50 months (range 12–78). We found a
rebound of disease in 43 patients (28.6%), with a 17
months medium disease-free period. Ten local recur-
rences, all in patients who underwent quadrantectomy,
have been detected.. Three patients had local recurrence
associated with lung metastases. No axillary recurrence
has been found in patients who had axillary node dissec-
tion. The perioperative mortality was 0% and there was a
18.6% mortality in five years.
Conclusion
Standard treatment for breast cancer usually involves
multi-modality treatment with a combination of surgery
and adjuvant therapies. These may include chemother-
apy, radiotherapy, endocrine therapy. The elderly receive
less aggressive treatment for breast cancer compared with
younger patients. Primary endocrine therapy is sometimes
substituted for operation, and axillary surgery, adjuvant
chemotherapy and adjuvant radiotherapy are commonly
omitted. Although most breast cancer patients are diag-
nosed at >65 years, historically an arbitrary cut-off of 70
years has been widely used, above which women were
considered for Tamoxifen-only treatment.
Older age is the most important risk factor for breast can-
cer, and because gains in life expectancy, particularly at
the end of life, will result in more women being at risk for
longer periods. Although available age-specific clinical tri-
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als data demonstrate that treatment efficacy is not modi-
fied by age, this efficacy evidence is limited by the lack of
inclusion of substantial numbers of older women, partic-
ularly those of advanced age and those with comorbidi-
ties. Our preliminary work has demonstrated correlation
between ER positivity and lower local recurrence (espe-
cially when treated with Tamoxifen) and improved breast
cancer specific survival, and between high tumour grade
and higher regional recurrence and poorer breast cancer
specific survival. Further work is underway to correlate
these features and other biological markers with long-
term clinical outcome. Elderly patients tolerate surgery
well. The risks from anaesthesia and surgery may have
been overestimated and the development of local anaes-
thetic techniques will help. Finally, there may also be
underestimation of life expectancy in elderly women. A 70
year-old woman currently has a life expectancy of 16
years, at age 80, 9 years. Even at age 90, a few additional
years can be expected. Age may have been used too rigidly
to decide local treatment for elderly patients with breast
cancer. Comprehensive multidisciplinary assessment is
needed to make informed decisions and to optimize man-
agement of elderly patients. Breast cancer therapy should
be defined by a woman's physiological age rather than
chronological age.Page 2 of 2
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